Variant interrupted DMPK alleles: Implications in the pathogenesis and molecular diagnosis of myotonic dystrophy type 1 (DM1)

Santoro Massimo, Masciullo Marcella, Novelli Giuseppe, Botta Annalisa

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Myotonic dystrophy type 1 (DM1) is an autosomal dominant neuromuscular disease caused by a pathological CTG repeat expansion in the 3'-untranslated region (UTR) of the DMPK gene on chromosome 19q13.2-q13.3. Although the CTG repeat tract is usually uninterrupted in both wild type and expanded alleles of DM1 patients, in the last years, pathological variants expansion containing unstable CCG, CTC and CGG sequence interruptions have been reported in rare instances. Complex variant repeats were identified at the 3'-end of the CTG array of DM1 patients of different origin, with an estimated prevalence of 3-5% of cases. The presence of interruptions within an otherwise homogeneous tract of repeats has been associated with a number of TREDs including FRAXA, SCA1, SCA2 and FRDA. In general, repeat interruptions lead to a stabilizing effect because of their ability to disrupt the formation of unusual DNA structures formed by "pure" repetitive sequences. The analysis of DM1 families reported so far in literature, straightens this hypothesis, indicating that interruptions in the CTG repeated tract render the expanded allele more stable, or could even predispose to its contraction during intergenerational transmissions. However, the phenotypical consequences of the interrupted alleles on DM1 patients is still controversial, leading to complex neurological phenotypes or mild later-onset forms. Changes in the sequence of the CTG array could modify the higher structure of the DMPK expanded transcripts and their interactions with RNA binding proteins. By influencing the nucleosome assembly across the repeat, interruptions can also modulate chromatin structure, which in turn may affect the cellular RNA metabolism. The identification of complex DMPK expansions has also important practical consequences for DM1 molecular genetic testing where they can lead to false negative conclusions. Moreover, because of the great uncertainty about the phenotypic consequences of interrupted DMPK alleles and their level of somatic mosaicism, the prediction of the clinical outcome is difficult in carriers of these alleles in DM1 genetic counseling.

Original languageEnglish
Title of host publicationMyotonic Dystrophies: Epidemiology, Diagnosis and Therapeutic Challenges
PublisherNova Science Publishers, Inc.
Pages121-137
Number of pages17
ISBN (Print)9781634829175, 9781634829052
Publication statusPublished - Jul 1 2015

Fingerprint

Myotonic Dystrophy
Alleles
Spinocerebellar Ataxias
Neuromuscular Diseases
Aptitude
Mosaicism
RNA-Binding Proteins
Nucleosomes
Nucleic Acid Repetitive Sequences
Genetic Counseling
Genetic Testing
3' Untranslated Regions
Uncertainty
Chromatin
Molecular Biology
Chromosomes
RNA
Phenotype
DNA
Genes

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Massimo, S., Marcella, M., Giuseppe, N., & Annalisa, B. (2015). Variant interrupted DMPK alleles: Implications in the pathogenesis and molecular diagnosis of myotonic dystrophy type 1 (DM1). In Myotonic Dystrophies: Epidemiology, Diagnosis and Therapeutic Challenges (pp. 121-137). Nova Science Publishers, Inc..

Variant interrupted DMPK alleles : Implications in the pathogenesis and molecular diagnosis of myotonic dystrophy type 1 (DM1). / Massimo, Santoro; Marcella, Masciullo; Giuseppe, Novelli; Annalisa, Botta.

Myotonic Dystrophies: Epidemiology, Diagnosis and Therapeutic Challenges. Nova Science Publishers, Inc., 2015. p. 121-137.

Research output: Chapter in Book/Report/Conference proceedingChapter

Massimo, S, Marcella, M, Giuseppe, N & Annalisa, B 2015, Variant interrupted DMPK alleles: Implications in the pathogenesis and molecular diagnosis of myotonic dystrophy type 1 (DM1). in Myotonic Dystrophies: Epidemiology, Diagnosis and Therapeutic Challenges. Nova Science Publishers, Inc., pp. 121-137.
Massimo S, Marcella M, Giuseppe N, Annalisa B. Variant interrupted DMPK alleles: Implications in the pathogenesis and molecular diagnosis of myotonic dystrophy type 1 (DM1). In Myotonic Dystrophies: Epidemiology, Diagnosis and Therapeutic Challenges. Nova Science Publishers, Inc. 2015. p. 121-137
Massimo, Santoro ; Marcella, Masciullo ; Giuseppe, Novelli ; Annalisa, Botta. / Variant interrupted DMPK alleles : Implications in the pathogenesis and molecular diagnosis of myotonic dystrophy type 1 (DM1). Myotonic Dystrophies: Epidemiology, Diagnosis and Therapeutic Challenges. Nova Science Publishers, Inc., 2015. pp. 121-137
@inbook{254e43b5503f43bf945b9fa39c3226a2,
title = "Variant interrupted DMPK alleles: Implications in the pathogenesis and molecular diagnosis of myotonic dystrophy type 1 (DM1)",
abstract = "Myotonic dystrophy type 1 (DM1) is an autosomal dominant neuromuscular disease caused by a pathological CTG repeat expansion in the 3'-untranslated region (UTR) of the DMPK gene on chromosome 19q13.2-q13.3. Although the CTG repeat tract is usually uninterrupted in both wild type and expanded alleles of DM1 patients, in the last years, pathological variants expansion containing unstable CCG, CTC and CGG sequence interruptions have been reported in rare instances. Complex variant repeats were identified at the 3'-end of the CTG array of DM1 patients of different origin, with an estimated prevalence of 3-5{\%} of cases. The presence of interruptions within an otherwise homogeneous tract of repeats has been associated with a number of TREDs including FRAXA, SCA1, SCA2 and FRDA. In general, repeat interruptions lead to a stabilizing effect because of their ability to disrupt the formation of unusual DNA structures formed by {"}pure{"} repetitive sequences. The analysis of DM1 families reported so far in literature, straightens this hypothesis, indicating that interruptions in the CTG repeated tract render the expanded allele more stable, or could even predispose to its contraction during intergenerational transmissions. However, the phenotypical consequences of the interrupted alleles on DM1 patients is still controversial, leading to complex neurological phenotypes or mild later-onset forms. Changes in the sequence of the CTG array could modify the higher structure of the DMPK expanded transcripts and their interactions with RNA binding proteins. By influencing the nucleosome assembly across the repeat, interruptions can also modulate chromatin structure, which in turn may affect the cellular RNA metabolism. The identification of complex DMPK expansions has also important practical consequences for DM1 molecular genetic testing where they can lead to false negative conclusions. Moreover, because of the great uncertainty about the phenotypic consequences of interrupted DMPK alleles and their level of somatic mosaicism, the prediction of the clinical outcome is difficult in carriers of these alleles in DM1 genetic counseling.",
author = "Santoro Massimo and Masciullo Marcella and Novelli Giuseppe and Botta Annalisa",
year = "2015",
month = "7",
day = "1",
language = "English",
isbn = "9781634829175",
pages = "121--137",
booktitle = "Myotonic Dystrophies: Epidemiology, Diagnosis and Therapeutic Challenges",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Variant interrupted DMPK alleles

T2 - Implications in the pathogenesis and molecular diagnosis of myotonic dystrophy type 1 (DM1)

AU - Massimo, Santoro

AU - Marcella, Masciullo

AU - Giuseppe, Novelli

AU - Annalisa, Botta

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Myotonic dystrophy type 1 (DM1) is an autosomal dominant neuromuscular disease caused by a pathological CTG repeat expansion in the 3'-untranslated region (UTR) of the DMPK gene on chromosome 19q13.2-q13.3. Although the CTG repeat tract is usually uninterrupted in both wild type and expanded alleles of DM1 patients, in the last years, pathological variants expansion containing unstable CCG, CTC and CGG sequence interruptions have been reported in rare instances. Complex variant repeats were identified at the 3'-end of the CTG array of DM1 patients of different origin, with an estimated prevalence of 3-5% of cases. The presence of interruptions within an otherwise homogeneous tract of repeats has been associated with a number of TREDs including FRAXA, SCA1, SCA2 and FRDA. In general, repeat interruptions lead to a stabilizing effect because of their ability to disrupt the formation of unusual DNA structures formed by "pure" repetitive sequences. The analysis of DM1 families reported so far in literature, straightens this hypothesis, indicating that interruptions in the CTG repeated tract render the expanded allele more stable, or could even predispose to its contraction during intergenerational transmissions. However, the phenotypical consequences of the interrupted alleles on DM1 patients is still controversial, leading to complex neurological phenotypes or mild later-onset forms. Changes in the sequence of the CTG array could modify the higher structure of the DMPK expanded transcripts and their interactions with RNA binding proteins. By influencing the nucleosome assembly across the repeat, interruptions can also modulate chromatin structure, which in turn may affect the cellular RNA metabolism. The identification of complex DMPK expansions has also important practical consequences for DM1 molecular genetic testing where they can lead to false negative conclusions. Moreover, because of the great uncertainty about the phenotypic consequences of interrupted DMPK alleles and their level of somatic mosaicism, the prediction of the clinical outcome is difficult in carriers of these alleles in DM1 genetic counseling.

AB - Myotonic dystrophy type 1 (DM1) is an autosomal dominant neuromuscular disease caused by a pathological CTG repeat expansion in the 3'-untranslated region (UTR) of the DMPK gene on chromosome 19q13.2-q13.3. Although the CTG repeat tract is usually uninterrupted in both wild type and expanded alleles of DM1 patients, in the last years, pathological variants expansion containing unstable CCG, CTC and CGG sequence interruptions have been reported in rare instances. Complex variant repeats were identified at the 3'-end of the CTG array of DM1 patients of different origin, with an estimated prevalence of 3-5% of cases. The presence of interruptions within an otherwise homogeneous tract of repeats has been associated with a number of TREDs including FRAXA, SCA1, SCA2 and FRDA. In general, repeat interruptions lead to a stabilizing effect because of their ability to disrupt the formation of unusual DNA structures formed by "pure" repetitive sequences. The analysis of DM1 families reported so far in literature, straightens this hypothesis, indicating that interruptions in the CTG repeated tract render the expanded allele more stable, or could even predispose to its contraction during intergenerational transmissions. However, the phenotypical consequences of the interrupted alleles on DM1 patients is still controversial, leading to complex neurological phenotypes or mild later-onset forms. Changes in the sequence of the CTG array could modify the higher structure of the DMPK expanded transcripts and their interactions with RNA binding proteins. By influencing the nucleosome assembly across the repeat, interruptions can also modulate chromatin structure, which in turn may affect the cellular RNA metabolism. The identification of complex DMPK expansions has also important practical consequences for DM1 molecular genetic testing where they can lead to false negative conclusions. Moreover, because of the great uncertainty about the phenotypic consequences of interrupted DMPK alleles and their level of somatic mosaicism, the prediction of the clinical outcome is difficult in carriers of these alleles in DM1 genetic counseling.

UR - http://www.scopus.com/inward/record.url?scp=84958686440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958686440&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84958686440

SN - 9781634829175

SN - 9781634829052

SP - 121

EP - 137

BT - Myotonic Dystrophies: Epidemiology, Diagnosis and Therapeutic Challenges

PB - Nova Science Publishers, Inc.

ER -